These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
370 related articles for article (PubMed ID: 16904848)
21. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond. Michiels JJ; Berneman Z; Schroyens W; De Raeve H Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092 [TBL] [Abstract][Full Text] [Related]
23. ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation. Hammarén HM; Ungureanu D; Grisouard J; Skoda RC; Hubbard SR; Silvennoinen O Proc Natl Acad Sci U S A; 2015 Apr; 112(15):4642-7. PubMed ID: 25825724 [TBL] [Abstract][Full Text] [Related]
24. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF). Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893 [TBL] [Abstract][Full Text] [Related]
25. Differential effect of inhibitory strategies of the V617 mutant of JAK2 on cytokine receptor signaling. Leroy E; Balligand T; Pecquet C; Mouton C; Colau D; Shiau AK; Dusa A; Constantinescu SN J Allergy Clin Immunol; 2019 Jul; 144(1):224-235. PubMed ID: 30707971 [TBL] [Abstract][Full Text] [Related]
26. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2 Hu M; Xu C; Yang C; Zuo H; Chen C; Zhang D; Shi G; Wang W; Shi J; Zhang T J Exp Clin Cancer Res; 2019 Feb; 38(1):49. PubMed ID: 30717771 [TBL] [Abstract][Full Text] [Related]
27. New insights into the pathogenesis of JAK2 V617F-positive myeloproliferative disorders and consequences for the management of patients. Villeval JL; James C; Pisani DF; Casadevall N; Vainchenker W Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):341-51. PubMed ID: 16810610 [TBL] [Abstract][Full Text] [Related]
28. Tyrosine-phosphorylated SOCS3 negatively regulates cellular transformation mediated by the myeloproliferative neoplasm-associated JAK2 V617F mutant. Funakoshi-Tago M; Tsuruya R; Ueda F; Ishihara A; Kasahara T; Tamura H; Tago K Cytokine; 2019 Nov; 123():154753. PubMed ID: 31255914 [TBL] [Abstract][Full Text] [Related]
29. [Analysis of oncogenic signaling pathway induced by a myeloproliferative neoplasm-associated Janus kinase 2 (JAK2) V617F mutant]. Funakoshi-Tago M Yakugaku Zasshi; 2012; 132(11):1267-72. PubMed ID: 23123718 [TBL] [Abstract][Full Text] [Related]
31. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia. Bellucci S; Michiels JJ Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614 [TBL] [Abstract][Full Text] [Related]
32. [Analysis of the mechanism of polycythemia vera by studying JAK2 mutant-induced signaling pathway]. Funakoshi-Tago M Yakugaku Zasshi; 2011; 131(8):1183-7. PubMed ID: 21804321 [TBL] [Abstract][Full Text] [Related]
33. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia. Teofili L; Giona F; Martini M; Cenci T; Guidi F; Torti L; Palumbo G; Amendola A; Foà R; Larocca LM J Clin Oncol; 2007 Mar; 25(9):1048-53. PubMed ID: 17369568 [TBL] [Abstract][Full Text] [Related]
35. In vitro expansion of erythroid progenitors from polycythemia vera patients leads to decrease in JAK2 V617F allele. Gaikwad A; Nussenzveig R; Liu E; Gottshalk S; Chang K; Prchal JT Exp Hematol; 2007 Apr; 35(4):587-95. PubMed ID: 17379069 [TBL] [Abstract][Full Text] [Related]
36. JAK2-V617F-mediated signalling is dependent on lipid rafts and statins inhibit JAK2-V617F-dependent cell growth. Griner LN; McGraw KL; Johnson JO; List AF; Reuther GW Br J Haematol; 2013 Jan; 160(2):177-87. PubMed ID: 23157224 [TBL] [Abstract][Full Text] [Related]
37. Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms. Hoermann G; Cerny-Reiterer S; Herrmann H; Blatt K; Bilban M; Gisslinger H; Gisslinger B; Müllauer L; Kralovics R; Mannhalter C; Valent P; Mayerhofer M FASEB J; 2012 Feb; 26(2):894-906. PubMed ID: 22051730 [TBL] [Abstract][Full Text] [Related]
38. Constitutive JunB expression, associated with the JAK2 V617F mutation, stimulates proliferation of the erythroid lineage. da Costa Reis Monte-Mór B; Plo I; da Cunha AF; Costa GG; de Albuquerque DM; Jedidi A; Villeval JL; Badaoui S; Lorand-Metze I; Pagnano KB; Saad ST; Vainchenker W; Costa FF Leukemia; 2009 Jan; 23(1):144-52. PubMed ID: 18843287 [TBL] [Abstract][Full Text] [Related]
39. Phosphorylated CIS suppresses the Epo or JAK2 V617F mutant-triggered cell proliferation through binding to EpoR. Funakoshi-Tago M; Moriwaki T; Ueda F; Tamura H; Kasahara T; Tago K Cell Signal; 2017 Feb; 31():41-57. PubMed ID: 28038963 [TBL] [Abstract][Full Text] [Related]
40. Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation. Lu X; Levine R; Tong W; Wernig G; Pikman Y; Zarnegar S; Gilliland DG; Lodish H Proc Natl Acad Sci U S A; 2005 Dec; 102(52):18962-7. PubMed ID: 16365288 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]